$MRNS
MARINUS PHARMACEUTICALS, INC.

2024 Q3 Form 10-Q Financial Statement

#000155837024011982 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $8.541M $8.056M
YoY Change 16.39% 32.48%
Cost Of Revenue $714.0K $735.0K
YoY Change 55.22% 90.41%
Gross Profit $7.827M $7.321M
YoY Change 13.76% 28.55%
Gross Profit Margin 91.64% 90.88%
Selling, General & Admin $12.57M $16.71M
YoY Change -15.44% 6.28%
% of Gross Profit 160.64% 228.25%
Research & Development $16.33M $20.90M
YoY Change -30.97% -2.41%
% of Gross Profit 208.69% 285.44%
Depreciation & Amortization $134.0K $140.0K
YoY Change -10.67% 10.24%
% of Gross Profit 1.71% 1.91%
Operating Expenses $28.91M $37.61M
YoY Change -24.97% 1.27%
Operating Profit -$21.08M -$32.24M
YoY Change -33.39% 2.54%
Interest Expense -$3.245M -$3.508M
YoY Change -176.5% -183.37%
% of Operating Profit
Other Income/Expense, Net $100.0K -$84.00K
YoY Change -90.21% -278.72%
Pretax Income -$24.23M -$35.83M
YoY Change -26.53% 7.04%
Income Tax
% Of Pretax Income
Net Earnings -$24.23M -$35.83M
YoY Change -26.53% 12.19%
Net Earnings / Revenue -283.63% -444.74%
Basic Earnings Per Share -$0.42 -$0.63
Diluted Earnings Per Share -$0.42 -$0.63
COMMON SHARES
Basic Shares Outstanding 55.08M 54.93M
Diluted Shares Outstanding 57.23M 57.06M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.18M $64.68M
YoY Change -76.08% -63.11%
Cash & Equivalents $42.20M $64.70M
Short-Term Investments
Other Short-Term Assets $4.660M $8.898M
YoY Change -60.17% -21.71%
Inventory $6.717M $4.873M
Prepaid Expenses
Receivables $3.840M $3.435M
Other Receivables $0.00 $0.00
Total Short-Term Assets $57.40M $81.88M
YoY Change -70.57% -57.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.882M $3.720M
YoY Change 24.89% -5.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.341M $1.481M
YoY Change -27.79% -44.18%
Total Long-Term Assets $6.223M $5.201M
YoY Change 7.93% -21.09%
TOTAL ASSETS
Total Short-Term Assets $57.40M $81.88M
Total Long-Term Assets $6.223M $5.201M
Total Assets $63.62M $87.08M
YoY Change -68.32% -56.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.707M $6.237M
YoY Change 41.17% 170.94%
Accrued Expenses $14.16M $15.23M
YoY Change -22.75% -14.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.48M $11.55M
YoY Change 75.0% 200.0%
Total Short-Term Liabilities $34.50M $35.87M
YoY Change 12.92% 40.09%
LONG-TERM LIABILITIES
Long-Term Debt $41.71M $45.08M
YoY Change -35.63% -33.85%
Other Long-Term Liabilities $54.15M $53.49M
YoY Change 6.38% 6.71%
Total Long-Term Liabilities $95.86M $98.56M
YoY Change -17.15% -16.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.50M $35.87M
Total Long-Term Liabilities $95.86M $98.56M
Total Liabilities $130.4M $134.4M
YoY Change -10.87% -6.56%
SHAREHOLDERS EQUITY
Retained Earnings -$670.6M -$646.4M
YoY Change 26.48% 30.01%
Common Stock $55.00K $55.00K
YoY Change 0.0% 7.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$66.74M -$47.35M
YoY Change
Total Liabilities & Shareholders Equity $63.62M $87.08M
YoY Change -68.32% -56.72%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$24.23M -$35.83M
YoY Change -26.53% 12.19%
Depreciation, Depletion And Amortization $134.0K $140.0K
YoY Change -10.67% 10.24%
Cash From Operating Activities -$19.45M -$30.84M
YoY Change -22.71% 26.62%
INVESTING ACTIVITIES
Capital Expenditures $1.114M $38.00K
YoY Change 1137.78%
Acquisitions
YoY Change
Other Investing Activities $0.00 $9.000M
YoY Change -100.0% 79.86%
Cash From Investing Activities -$1.114M $8.962M
YoY Change -109.35% 79.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.925M -17.70M
YoY Change -107.43% -7567.51%
NET CHANGE
Cash From Operating Activities -19.45M -30.84M
Cash From Investing Activities -1.114M 8.962M
Cash From Financing Activities -1.925M -17.70M
Net Change In Cash -22.49M -39.58M
YoY Change -277.66% 107.03%
FREE CASH FLOW
Cash From Operating Activities -$19.45M -$30.84M
Capital Expenditures $1.114M $38.00K
Free Cash Flow -$20.57M -$30.88M
YoY Change -18.58% 26.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesNoncurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001267813
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesNoncurrent
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36576
dei Entity Registrant Name
EntityRegistrantName
MARINUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0198082
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Radnor Corporate Center, Suite 500
dei Entity Address Address Line2
EntityAddressAddressLine2
100 Matsonford Rd
dei Entity Address City Or Town
EntityAddressCityOrTown
Radnor
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
801-4670
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MRNS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55084038
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64676000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120572000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29716000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3435000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3799000
CY2024Q2 us-gaap Inventory Net
InventoryNet
4873000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2413000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8898000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8746000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
81882000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
165246000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3720000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3843000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1481000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1819000
CY2024Q2 us-gaap Assets
Assets
87083000
CY2023Q4 us-gaap Assets
Assets
170908000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6237000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4003000
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
11550000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11551000
CY2024Q2 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2849000
CY2023Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2211000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15231000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35867000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40624000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
45075000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
61423000
CY2024Q2 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
35431000
CY2023Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
33766000
CY2024Q2 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
17844000
CY2023Q4 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
17545000
CY2024Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
211000
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
785000
CY2024Q2 us-gaap Liabilities
Liabilities
134428000
CY2023Q4 us-gaap Liabilities
Liabilities
154143000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54971226
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54963919
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54585428
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54578121
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
55000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
599023000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
588656000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-646423000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-571926000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-47345000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16765000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87083000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170908000
CY2024Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
87000
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1814000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
239000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
8862000
CY2024Q2 us-gaap Revenues
Revenues
8056000
CY2023Q2 us-gaap Revenues
Revenues
6081000
us-gaap Revenues
Revenues
15735000
us-gaap Revenues
Revenues
16461000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20897000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21412000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45015000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49345000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16710000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15722000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35336000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30926000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
1950000
us-gaap Restructuring Charges
RestructuringCharges
1950000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
40292000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
37520000
us-gaap Costs And Expenses
CostsAndExpenses
83792000
us-gaap Costs And Expenses
CostsAndExpenses
80863000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32236000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31439000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68057000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64402000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1109000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2128000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2571000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4471000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4617000
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4208000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
8963000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
8355000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-84000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
84000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35828000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33472000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74497000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68202000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35828000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31934000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74497000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66664000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57064095
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57064095
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52551918
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52551918
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56957953
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56957953
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52162962
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52162962
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-188000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
20000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-114000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35828000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32122000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74477000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66778000
us-gaap Profit Loss
ProfitLoss
-74497000
us-gaap Profit Loss
ProfitLoss
-66664000
us-gaap Depreciation
Depreciation
271000
us-gaap Depreciation
Depreciation
284000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1246000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1102000
mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
2106000
mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
2916000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
149000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
669000
us-gaap Share Based Compensation
ShareBasedCompensation
10110000
us-gaap Share Based Compensation
ShareBasedCompensation
7632000
mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
741000
mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
837000
mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
443000
mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
102000
mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
87000
mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
196000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
62000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
757000
mrns Financing Costs Included In Interest Expense
FinancingCostsIncludedInInterestExpense
300000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1040000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1569000
mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
3160000
mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
7441000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6115000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4088000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68302000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65836000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
29885000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
5000000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
51995000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29847000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46991000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
257000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
484000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
17698000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-421000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-17441000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55896000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-112764000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120572000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240551000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64676000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127787000
mrns Unrealized Gain Loss On Short Term Investments Cash Flow
UnrealizedGainLossOnShortTermInvestmentsCashFlow
20000
mrns Unrealized Gain Loss On Short Term Investments Cash Flow
UnrealizedGainLossOnShortTermInvestmentsCashFlow
-114000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000
us-gaap Interest Paid Net
InterestPaidNet
5611000
us-gaap Interest Paid Net
InterestPaidNet
4336000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
163000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
116000000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3741000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34730000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
85085000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3891000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
485000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-188000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31934000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57339000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16765000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5193000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
20000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-38669000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-16434000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4917000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-35828000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-47345000
us-gaap Net Income Loss
NetIncomeLoss
-74500000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-646400000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
mrns Number Of Customers
NumberOfCustomers
3
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
mrns Number Of Customers
NumberOfCustomers
3
mrns Trade Receivable Payment Term
TradeReceivablePaymentTerm
P30D
CY2024Q2 us-gaap Cash
Cash
1000000.0
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
63700000
CY2023Q4 us-gaap Cash
Cash
1300000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
119300000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
200000
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29736000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
169000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
189000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29716000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
3200000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
436000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
945000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1075000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
728000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
902000
CY2024Q2 us-gaap Inventory Net
InventoryNet
4873000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2413000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3783000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7746000
CY2024Q2 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
3764000
CY2023Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
4701000
CY2023Q4 mrns Accrued License Agreement Payment
AccruedLicenseAgreementPayment
4000000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1269000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2024Q2 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
4475000
CY2023Q4 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
3901000
CY2024Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
952000
CY2024Q2 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
778000
CY2023Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
774000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
501000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15231000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11308734
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8709269
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4917000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3891000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10110000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7632000
CY2022Q4 mrns Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.0999
CY2022Q4 mrns Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.1999
CY2020Q3 mrns Maximum Shares Available For Issuance Value Equity Distribution Agreement
MaximumSharesAvailableForIssuanceValueEquityDistributionAgreement
75000000
mrns Equity Distribution Agreement Commission Percentage Maximum
EquityDistributionAgreementCommissionPercentageMaximum
0.030
mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2023Q2 mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2024Q2 mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2024Q2 mrns Maximum Shares Available For Issuance Value Equity Distribution Agreement
MaximumSharesAvailableForIssuanceValueEquityDistributionAgreement
48600000
CY2024Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P78M
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P60M
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P15M
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1000000.0
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1400000
us-gaap Lease Cost
LeaseCost
1300000
us-gaap Lease Cost
LeaseCost
300000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
800000
CY2024Q2 us-gaap Lease Cost
LeaseCost
1000000.0
CY2023Q2 us-gaap Lease Cost
LeaseCost
100000
CY2024Q2 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
800000
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.110
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
800000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
422000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
641000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1063000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
74000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
989000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
778000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
989000
CY2024Q2 mrns Debt Instrument Principal Payments Reduction Percentage
DebtInstrumentPrincipalPaymentsReductionPercentage
0.50
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
58100000
CY2024Q2 mrns Debt Instrument Minimum Liquidity Covenant
DebtInstrumentMinimumLiquidityCovenant
15000000.0
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2024Q2 mrns Contractual Term Loan Exit Fees
ContractualTermLoanExitFees
2003000
CY2024Q2 mrns Debt Instrument Principal Payment Including Associated Exit Fee
DebtInstrumentPrincipalPaymentIncludingAssociatedExitFee
17326000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3052000
CY2024Q2 us-gaap Notes Payable
NotesPayable
56625000
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
11550000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
45075000
CY2024Q2 us-gaap Notes Payable
NotesPayable
56625000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15000000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
39375000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
58125000
CY2024Q1 mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
2600000
mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
100000
mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.17
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
30877000
mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
2916000
mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
134000
mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-421000
CY2023Q2 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
33506000
CY2023Q2 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
1556000
CY2023Q2 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
31950000
CY2023Q2 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
33506000
CY2023Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
35977000
mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
3156000
mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
197000
mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-1050000
CY2024Q2 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
38280000
CY2024Q2 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2849000
CY2024Q2 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
35431000
CY2024Q2 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
38280000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
400000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
500000
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.20
us-gaap Restructuring Charges
RestructuringCharges
2000000.0
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
1000000.0
us-gaap Payments For Restructuring
PaymentsForRestructuring
670000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
330000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
952000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011982-index-headers.html Edgar Link pending
0001558370-24-011982-index.html Edgar Link pending
0001558370-24-011982.txt Edgar Link pending
0001558370-24-011982-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrns-20240630.xsd Edgar Link pending
mrns-20240630x10q.htm Edgar Link pending
mrns-20240630x10q004.jpg Edgar Link pending
mrns-20240630x10q007.jpg Edgar Link pending
mrns-20240630xex31d1.htm Edgar Link pending
mrns-20240630xex31d2.htm Edgar Link pending
mrns-20240630xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mrns-20240630_cal.xml Edgar Link unprocessable
mrns-20240630_def.xml Edgar Link unprocessable
mrns-20240630_lab.xml Edgar Link unprocessable
mrns-20240630_pre.xml Edgar Link unprocessable
mrns-20240630x10q_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending